A Review of Pharmacotherapy for Chronic Low Back Pain with Considerations for Sports Medicine

References

• . Bono CM. Low-back pain in athletes. J Bone Joint Surg Am. 2004;86–A(2):382–396
   Google Scholar
• . Dreisinger TE, Nelson B. Management of back pain in athletes. Sports Med. 1996;21(4):313–320
   PubMedGoogle Scholar
• . McCarroll JR, Miller JM, Ritter MA. Lumbar spondylolysis and spondylolisthesis in college football players. A prospective study. Am J Sports Med. 1986;14(5):404–406
   PubMedGoogle Scholar
• . Lundin O, Hellström M, Nilsson I, Swärd L. Back pain and radiological changes in the thoraco-lumbar spine of athletes. A long-term follow-up. Scand J Med Sci Sports. 2001;11(2):103–109
   PubMed Web of Science ®Google Scholar
• . Bahr R, Andersen SO, Løken S, Fossan B, Hansen T, Holme I. Low back pain among endurance athletes with and without specific back loading—a cross-sectional survey of cross-country skiers, rowers, orienteerers, and nonathletic controls. Spine (Phila Pa 1976). 2004; 29(4):449–454
   PubMed Web of Science ®Google Scholar
• . McHardy A, Pollard H. Lower back pain in golfers: a review of the literature. J Chiropr Med. 2005;4(3):135–143
   PubMedGoogle Scholar
• . Xu G, Pang D, Liu F, Pei D, Wang S, Li L. Prevalence of low back pain and associated occupational factors among Chinese coal miners. BMC Public Health. 2012;12:149
   PubMedGoogle Scholar
• . Mitchell T, O'Sullivan PB, Burnett AF, Straker L, Rudd C. Low back pain characteristics from undergraduate student to working nurse in Australia: a cross-sectional survey. Int J Nurs Stud. 2008;45(11):1636–1644
   PubMedGoogle Scholar
• . O'Sullivan D, Cunningham C, Blake C. Low back pain among Irish farmers. Occup Med (Lond). 2009;59(1):59–61
   PubMedGoogle Scholar
• . Chou R, Qaseem A, Snow V, . Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147(7):478–491
   PubMed Web of Science ®Google Scholar
• . Wand BM, O'Connell NE. Chronic non-specific low back pain- sub-groups or a single mechanism? BMC Musculoskelet Disord. 2008;9:11
   PubMed Web of Science ®Google Scholar
• . Heuch I, Hagen K, Nygaard Ø, Zwart JA. The impact of body mass index on the prevalence of low back pain: the HUNT study. Spine (Phila Pa 1976). 2010;35(7):764–768
   PubMed Web of Science ®Google Scholar
• . Freburger JK, Holmes GM, Agans RP, . The rising prevalence of chronic low back pain. Arch Intern Med. 2009;169(3):251–258
   PubMed Web of Science ®Google Scholar
• . Schaafsma F, Schonstein E, Whelan KM, Ulvestad E, Kenny DT, Verbeek JH. Physical conditioning programs for improving work outcomes in workers with back pain. Cochrane Database Syst Rev. 2010(1):CD001822
   Google Scholar
• . Perich D, Burnett A, O'Sullivan P, Perkin C. Low back pain in adolescent female rowers: a multi-dimensional intervention study. Knee Surg Sports Traumatol Arthrosc. 2011;19(1):20–29
   PubMed Web of Science ®Google Scholar
• . Teixeira LA, de Oliveira DL, Romano RG, Correa SC. Leg preference and interlateral asymmetry of balance stability in soccer players. Res Q Exerc Sport. 2011;82(1):21–27
   PubMed Web of Science ®Google Scholar
• . Murray E, Birley E, Twycross-Lewis R, Morrissey D. The relationship between hip rotation range of movement and low back pain prevalence in amateur golfers: an observational study. Phys Ther Sport. 2009;10(4):131–135
   PubMedGoogle Scholar
• . van Middelkoop M, Rubinstein SM, Verhagen AP, Ostelo RW, Koes BW, van Tulder MW. Exercise therapy for chronic nonspecific low-back pain. Best Pract Res Clin Rheumatol. 2010;24(2):193–204
   PubMed Web of Science ®Google Scholar
• . Baker RJ, Patel D. Lower back pain in the athlete: common conditions and treatment. Prim Care. 2005;32(1):201–229
   PubMed Web of Science ®Google Scholar
• . Davies RA, Maher CG, Hancock MJ. A systematic review of paracetamol for non-specific low back pain. Eur Spine J. 2008;17(11):1423–1430
   PubMedGoogle Scholar
• . Kondric M, Sekulic D, Petroczi A, Ostojic L, Rodek J, Ostojic Z. Is there a danger for myopia in anti-doping education? Comparative analysis of substance use and misuse in Olympic racket sports calls for a broader approach. Subst Abuse Treat Prev Policy. 2011;6:27
   PubMed Web of Science ®Google Scholar
• . Benedetti F, Pollo A, Colloca L. Opioid-mediated placebo responses boost pain endurance and physical performance: is it doping in sport competitions? J Neurosci. 2007;27(44):11934–11939
   PubMedGoogle Scholar
• . Andersson GB. Epidemiological features of chronic low-back pain. Lancet. 1999;354(9178):581–585
   PubMed Web of Science ®Google Scholar
• . Muthukrishnan R, Shenoy SD, Jaspal SS, Nellikunja S, Fernandes S. The differential effects of core stabilization exercise regime and conventional physiotherapy regime on postural control parameters during perturbation in patients with movement and control impairment chronic low back pain. Sports Med Arthrosc Rehabil Ther Technol. 2010;2:13
   PubMedGoogle Scholar
• . Harringe ML, Nordgren JS, Arvidsson I, Werner S. Low back pain in young female gymnasts and the effect of specific segmental muscle control exercises of the lumbar spine: a prospective controlled intervention study. Knee Surg Sports Traumatol Arthrosc. 2007;15(10):1264–1271
   PubMedGoogle Scholar
• . Kristensen J, Franklyn-Miller A. Resistance training in musculoskeletal rehabilitation: a systematic review. Br J Sports Med. 2012;46(10):719–726
   PubMedGoogle Scholar
• . Dvorak H, Kujat C, Brumitt J. Effect of therapeutic exercise versus manual therapy on athletes with chronic low back pain. J Sport Rehabil. 2011;20(4):494–504
   PubMedGoogle Scholar
• . Petering RC, Webb C. Treatment options for low back pain in athletes. Sports Health. 2011;3(6):550–555
   PubMedGoogle Scholar
• . Peniston JH. Pharmacotherapy for chronic low back pain. In: Sakai Y, ed. Low Back Pain Pathogenesis and Treatment. Rijeka, Croatia: InTech; 2012: 115–138
   Google Scholar
• . Altman RD, Smith HS. Opioid therapy for osteoarthritis and chronic low back pain. Postgrad Med. 2010;122(6):87–97
   PubMed Web of Science ®Google Scholar
• . Parr AT, Manchikanti L, Hameed H, . Caudal epidural injections in the management of chronic low back pain: a systematic appraisal of the literature. Pain Physician. 2012;15(3):E159–E198
   PubMed Web of Science ®Google Scholar
• . Airaksinen O, Brox JI, Cedraschi C, . Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J. 2006;15( suppl 2):S192–S300
   PubMed Web of Science ®Google Scholar
• . Morlion B. Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. Curr Med Res Opin. 2011;27(1):11–33
   PubMed Web of Science ®Google Scholar
• . Zhang W, Nuki G, Moskowitz RW, . OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18(4):476–499
   PubMed Web of Science ®Google Scholar
• . Wolf DA, Miller TW, Pescatello LS, Barnes C. National collegiate athletic association division I athletes' use of nonprescription medication. Sports Health. 2011;3(1):25–28
   PubMedGoogle Scholar
• . Watkins PB, Kaplowitz N, Slattery JT, . Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87–93
   PubMed Web of Science ®Google Scholar
• . Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol. 2009;43(4):342–349
   PubMed Web of Science ®Google Scholar
• . Kuehn BM. FDA focuses on drugs and liver damage: labeling and other changes for acetaminophen. JAMA. 2009;302(4):369–371
   PubMedGoogle Scholar
• . Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review. Spine (Phila Pa 1976). 2008;33(16):1766–1774
   PubMed Web of Science ®Google Scholar
• . Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, Schnitzer TJ. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004;51(5):746–754
   PubMedGoogle Scholar
• . Boers M, Tangelder MJ, van Ingen H, Fort JG, Goldstein JL. The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of12 randomised trials. Ann Rheum Dis. 2007;66(3):417–418
   PubMedGoogle Scholar
• . Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115(10):787–796
   PubMed Web of Science ®Google Scholar
• . Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;331(7528):1310–1316
   PubMed Web of Science ®Google Scholar
• . Barkin RL, Buvanendran A. Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs. Am J Ther. 2004;11(2):124–129
   PubMedGoogle Scholar
• . Evans JM, McGregor E, McMahon AD, . Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM. 1995;88(8):551–557
   PubMed Web of Science ®Google Scholar
• . Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2004;20(4):373–380
   PubMed Web of Science ®Google Scholar
• . Rostom A, Muir K, Dubé C, . Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5(7):818–828, 828 e1–5;quiz 768
   PubMed Web of Science ®Google Scholar
• . Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634–1642
   PubMed Web of Science ®Google Scholar
• . Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99(3):132–140
   PubMed Web of Science ®Google Scholar
• . Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330(7504):1366
   PubMed Web of Science ®Google Scholar
• . Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021–2029
   PubMed Web of Science ®Google Scholar
• . Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials. BMJ. 2006;332(7553):1302–1308
   PubMed Web of Science ®Google Scholar
• . Motsko SP, Rascati KL, Busti AJ, . Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf. 2006;29(7):621–632
   PubMed Web of Science ®Google Scholar
• . Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension. 2005;46(3):500–507
   PubMed Web of Science ®Google Scholar
• . Tulner LR, Frankfort SV, Gijsen GJ, van Campen JP, Koks CH, Beijnen JH. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging. 2008;25(4):343–355
   PubMed Web of Science ®Google Scholar
• . American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331–1346
   PubMed Web of Science ®Google Scholar
• . Malhotra S, Karan RS, Pandhi P, Jain S. Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance. Postgrad Med J. 2001;77(913):703–707
   PubMed Web of Science ®Google Scholar
• . Cheetham TC, Levy G, Niu F, Bixler F. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. Ann Pharmacother. 2009;43(11):1765–1773
   PubMedGoogle Scholar
• . American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331–1346
   PubMed Web of Science ®Google Scholar
• . Ho PM, Maddox TM, Wang L, . Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937–944
   PubMed Web of Science ®Google Scholar
• . Juurlink DN, Gomes TG, Ko TK, . A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713–718
   PubMed Web of Science ®Google Scholar
• . Singh G, Fort JG, Goldstein JL, . Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006;119(3):255–266
   PubMed Web of Science ®Google Scholar
• . O'Connor JP, Lysz T. Celecoxib, NSAIDs and the skeleton. Drugs Today (Barc). 2008;44(9):693–709
   PubMed Web of Science ®Google Scholar
• . Houglum JE. Pharmacologic considerations in the treatment of injured athletes with nonsteroidal anti-inflammatory drugs. J Athl Train. 1998;33(3):259–263
   PubMedGoogle Scholar
• . Mason L, Moore RA, Edwards JE, McQuay HJ, Derry S, Wiffen PJ. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ. 2004;328(7446):995
   PubMed Web of Science ®Google Scholar
• . Waikakul S, Danputipong P, Soparat K. Topical analgesics, indomethacin plaster and diclofenac emulgel for low back pain: a parallel study. J Med Assoc Thai. 1996;79(8):486–490
   PubMedGoogle Scholar
• . Frerick H, Keitel W, Kuhn U, Schmidt S, Bredehorst A, Kuhlmann M. Topical treatment of chronic low back pain with a capsicum plaster. Pain. 2003;106(1–2):59–64
   PubMedGoogle Scholar
• . Keitel W, Frerick H, Kuhn U, Schmidt U, Kuhlmann M, Bredehorst A. Capsicum pain plaster in chronic non-specific low back pain. Arzneimittelforschung. 2001;51(11):896–903
   PubMed Web of Science ®Google Scholar
• . Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1994;37(1):1–9
   PubMedGoogle Scholar
• . Chan TY. Potential dangers from topical preparations containing methyl salicylate. Hum Exp Toxicol. 1996;15(9):747–750
   PubMed Web of Science ®Google Scholar
• . Bell AJ, Duggin G. Acute methyl salicylate toxicity complicating herbal skin treatment for psoriasis. Emerg Med (Fremantle). 2002;14(2):188–190
   PubMedGoogle Scholar
• . Davies MG, Briffa DV, Greaves MW. Systemic toxicity from topically applied salicylic acid. BMJ. 1979;1(6164):661
   PubMedGoogle Scholar
• . Péc J, Strmenová M, Palencárová E, . Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis. Cutis. 1992;50(4):307–309
   PubMed Web of Science ®Google Scholar
• . Tanen DA, Danish DC, Reardon JM, Chisholm CB, Matteucci MJ, Riffenburgh RH. Comparison of oral aspirin versus topical applied methyl salicylate for platelet inhibition. Ann Pharmacother. 2008;42(10):1396–1401
   PubMed Web of Science ®Google Scholar
• . Heng MC. Local necrosis and interstitial nephritis due to topical methyl salicylate and menthol. Cutis. 1987;39(5):442–444
   PubMed Web of Science ®Google Scholar
• . Yip AS, Chow WH, Tai YT, Cheung KL. Adverse effect of topical methylsalicylate ointment on warfarin anticoagulation: an unrecognized potential hazard. Postgrad Med J. 1990;66(775):367–369
   PubMed Web of Science ®Google Scholar
• . Joss JD, LeBlond RF. Potentiation of warfarin anticoagulation associated with topical methyl salicylate. Ann Pharmacother. 2000;34(6):729–733
   PubMed Web of Science ®Google Scholar
• . Associated Press. Muscle-pain reliever is blamed for Staten Island runner's death. New York Times. June 10, 2007:New York/Region
   Google Scholar
• . Voltaren^® Gel 1% (diclofenac sodium topical gel) [full prescribing information]. Parsippany, NJ: Novartis Consumer Health, Inc; 2009
   Google Scholar
• . Pennsaid^® (diclofenac sodium topical solution) [full prescribing information]. Varennes, Quebec, Canada: Nuvo Manufacturing; 2010
   Google Scholar
• . Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch Intern Med. 2002;162(1):19–24
   PubMedGoogle Scholar
• . Staiger TO, Gaster B, Sullivan MD, Deyo RA. Systematic review of antidepressants in the treatment of chronic low back pain. Spine (Phila Pa 1976). 2003;28(22):2540–2545
   PubMed Web of Science ®Google Scholar
• . Skljarevski V, Desaiah D, Liu-Seifert H, . Efficacy and safety of duloxetine in patients with chronic low back pain. Spine (Phila Pa 1976). 2010;35(13):E578–E585
   PubMed Web of Science ®Google Scholar
• . Skljarevski V, Ossanna M, Liu-Seifert H, . A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol. 2009;16(9):1041–1048
   PubMed Web of Science ®Google Scholar
• . Skljarevski V, Zhang S, Chappell AS, Walker DJ, Murray I, Backonja M. Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study. Pain Med. 2010;11(5):648–657
   PubMed Web of Science ®Google Scholar
• . Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613–624
   PubMed Web of Science ®Google Scholar
• . Cymbalta^® (duloxetine hydrochloride) [full prescribing information]: Indianapolis, IN: Eli Lilly and Company; 2011
   Google Scholar
• . Rich BA, Webster LR. A review of forensic implications of opioid prescribing with examples from malpractice cases involving opioid-related overdose. Pain Med. 2011;12( suppl 2):S59–S65
   PubMed Web of Science ®Google Scholar
• . Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–442
   PubMed Web of Science ®Google Scholar
• . Butler SF, Budman SH, Fernandez KC, . Development and validation of the Current Opioid Misuse Measure. Pain. 2007;130(1–2):144–156
   PubMed Web of Science ®Google Scholar
• . Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients With Pain (SOAPP-R). J Pain. 2008;9(4):360–372
   PubMed Web of Science ®Google Scholar
• . Cone EJ, Caplan YH. Urine toxicology testing in chronic pain management. Postgrad Med. 2009;121(4):91–102
   PubMed Web of Science ®Google Scholar
• . Manchikanti L, Atluri S, Trescot AM, Giordano J. Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility. Pain Physician. 2008;11( 2 suppl):S155–S180
   PubMed Web of Science ®Google Scholar
• . Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107–112
   PubMed Web of Science ®Google Scholar
• . Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin. 2009;25(9):2133–2150
   PubMed Web of Science ®Google Scholar
• . Benyamin R, Trescot AM, Datta S, . Opioid complications and side effects. Pain Physician. 2008;11( 2 suppl):S105–S120
   PubMed Web of Science ®Google Scholar
• . Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74(8):1347–1354
   PubMed Web of Science ®Google Scholar
• . Cottler LB, Ben Abdallah A, Cummings SM, Barr J, Banks R, Forchheimer R. Injury, pain, and prescription opioid use among former National Football League (NFL) players. Drug Alcohol Depend. 2011;116(1–3):188–194
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers - United States, 1999–2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487–1492
   PubMedGoogle Scholar
• . Sottas PE, Robinson N, Rabin O, Saugy M. The athlete biological passport. Clin Chem. 2011;57(7):969–976
   PubMed Web of Science ®Google Scholar
• . Calfee R, Fadale P. Popular ergogenic drugs and supplements in young athletes. Pediatrics. 2006;117(3):e577–e589
   PubMed Web of Science ®Google Scholar
• . Sellers EM, Schoedel KA, Romach MK. Update on formulations to deter tampering. Presented at: College on Problems of Drug Dependence 73rd Annual Scientific Meeting; June 2011; Hollywood, FL
   Google Scholar
• . Müller FO, Odendaal CL, Müller FR, Raubenheimer J, Middle MV, Kummer M. Comparison of the efficacy and tolerability of a paracetamol/codeine fixed-dose combination with tramadol in patients with refractory chronic back pain. Arzneimittelforschung. 1998;48(6):675–679
   PubMed Web of Science ®Google Scholar
• . Vad VB, Bhat AL, Tarabichi Y. The role of the Back Rx exercise program in diskogenic low back pain: a prospective randomized trial. Arch Phys Med Rehabil. 2007;88(5):577–582
   PubMedGoogle Scholar
• . Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174(11):1589–1594
   PubMed Web of Science ®Google Scholar
• . Deshpande A, Furlan A, Mailis-Gagnon A, Atlas S, Turk D. Opioids for chronic low-back pain. Cochrane Database Syst Rev. 2007;(3): CD004959
   Google Scholar
• . Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine. 1998;23(23):2591–2600
   PubMed Web of Science ®Google Scholar
• . Rauck RL, Bookbinder SA, Bunker TR, . The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag. 2006;2(3):155–166
   PubMedGoogle Scholar
• . Rauck RL, Bookbinder SA, Bunker TR, . A randomized, open-label study of once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: the extension phase of the ACTION trial. J Opioid Manag. 2006;2(6):325–328, 331–323
   PubMedGoogle Scholar
• . Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain. 2006;7(12):937–946
   PubMed Web of Science ®Google Scholar
• . Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternateday dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend. 2000;58(1–2):143–152
   PubMed Web of Science ®Google Scholar
• . Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain. 2005;6(6):392–399
   PubMed Web of Science ®Google Scholar
• . Hale ME, Ahdieh H, Ma T, Rauck R; Oxymorphone ER Study Group 1. Efficacy and safety of Opana ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8(2):175–184
   PubMed Web of Science ®Google Scholar
• . Katz N, Rauck R, Ahdieh H, . A 12-week randomized placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007;23(1):117–128
   PubMed Web of Science ®Google Scholar
• . Peniston JH, Gould E. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. Clin Ther. 2009;31(2):347–359
   PubMedGoogle Scholar
• . Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study. Int J Clin Pract. 2007;61(10):1671–1676
   PubMedGoogle Scholar
• . Wallace M, Thipphawong J. Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain [published online ahead of print. Pain Med. 2010;11(10):1477–1488
   PubMedGoogle Scholar
• . Sathyan G, Sivakumar K, Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin. 2008;24(1):297–305
   PubMed Web of Science ®Google Scholar
• . FDA asks Purdue Pharma to withdraw Palladone. FDA Consum. 2005;39(5):7
   Google Scholar
• . Simpson RK Jr, Edmondson EA, Constant CF, Collier C. Transdermal fentanyl as treatment for chronic low back pain. J Pain Symptom Manage. 1997;14(4):218–224
   PubMedGoogle Scholar
• . Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine (Phila Pa 1976). 2005;30(22):2484–2490
   PubMed Web of Science ®Google Scholar
• . Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497–504
   PubMed Web of Science ®Google Scholar
• . Haberer JP, Schoeffler P, Couderc E, Duvaldestin P. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth. 1982;54(12):1267–1270
   PubMedGoogle Scholar
• . Duragesic^® (fentanyl transdermal system) [full prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals; 2009
   Google Scholar
• . Gordon A, Rashiq S, Moulin DE, . Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag. 2010;15(3):169–178
   PubMed Web of Science ®Google Scholar
• . Grilo RM, Bertin P, Scotto di Fazano C, . Opioid rotation in the treatment of joint pain. A review of 67 cases. Joint Bone Spine. 2002;69(5):491–494
   PubMed Web of Science ®Google Scholar
• . Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32(4):304–315
   PubMed Web of Science ®Google Scholar
• . Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg. 2000;90(4):933–937
   PubMed Web of Science ®Google Scholar
• . Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372–380
   PubMed Web of Science ®Google Scholar
• . Hoy SM. Tapentadol extended release: in adults with chronic pain. Drugs. 2012;72(3):375–393
   PubMed Web of Science ®Google Scholar
• . Ultram ER^® (tramadol hydrochloride) [full prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2009
   Google Scholar
• . O'Donnell JB, Ekman EF, Spalding WM, Bhadra P, McCabe D, Berger MF. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res. 2009;37(6):1789–1802
   PubMed Web of Science ®Google Scholar
• . Peloso PM, Fortin L, Beaulieu A, Kamin M, Rosenthal N. Analgesic efficacy and safety of tramadol/acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial. J Rheumatol. 2004;31(12):2454–2463
   PubMed Web of Science ®Google Scholar
• . Ruoff GE, Rosenthal N, Jordan D, Karim R, Kamin M; Protocol CAPSS-112 Study Group. Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study. Clin Ther. 2003;25(4):1123–1141
   PubMed Web of Science ®Google Scholar
• . Schnitzer TJ, Gray WL, Paster RZ, Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J Rheumatol. 2000;27(3):772–778
   PubMed Web of Science ®Google Scholar
• . Kneip C, Terlinden R, Beier H, Chen G. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008;2(1):67–75
   PubMedGoogle Scholar
• . Tzschentke TM, Christoph T, Kogel B, . (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323(1):265–276
   PubMed Web of Science ®Google Scholar
• . Lange B, Kuperwasser B, Okamoto A, . Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010;27(6):381–399
   PubMed Web of Science ®Google Scholar
• . Peniston JH, Potts SL, Hu X, Wieman MS. Safety of oxymorphone extended release with selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. Presented at: American Academy of Pain Management; September 2011; Las Vegas, NV
   Google Scholar
• . Nucynta^® (tapentadol) [full prescribing information] Titusville, NJ: Janssen Pharmaceuticals Inc.; 2012
   Google Scholar
• . Gross DP, Bhambhani Y, Haykowsky MJ, Rashiq S. Acute opioid administration improves work-related exercise performance in patients with chronic back pain. J Pain. 2008;9(9):856–862
   PubMedGoogle Scholar
• . Schein JR, Kosinski MR, Janagap-Benson C, Gajria K, Lin P, Freedman JD. Functionality and health-status benefits associated with reduction of osteoarthritis pain. Curr Med Res Opin. 2008;24(5):1255–1265
   PubMed Web of Science ®Google Scholar
• . Soin A, Cheng J, Brown L, Moufawad S, Mekhail N. Functional outcomes in patients with chronic nonmalignant pain on long-term opioid therapy. Pain Pract. 2008;8(5):379–384
   PubMedGoogle Scholar
• . Teske W, Anastasiadis A, Krämer J, Theodoridis T. [Effective pain relief facilitates exercise therapy: results of a multicenter study with controlled-release oxycodone in patients with movement pain] [published online ahead of print Effektive Schmerzlinderung ermoglicht Bewegungstherapie: Ergebnisse einer Multicenterstudie mit retardiertem Oxycodon bei Patienten mit Bewegungsschmerz.]. Orthopade. 2008;37(12):1210–1216
   PubMedGoogle Scholar
• . Williams GW. An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors. Curr Pain Headache Rep. 2005;9(6):377–389
   PubMedGoogle Scholar
• . Manchikanti L, Abdi S, Atluri S, ; American Society of Interventional Pain Physicians. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2—guidance. Pain Physician. 2012;15( 3 suppl):S67–S116
   PubMed Web of Science ®Google Scholar
• . Rastogi R, Swarm RA, Patel TA. Case scenario: opioid association with serotonin syndrome: implications to the practitioners. Anesthesiology. 2011;115(6);1291–1298
   PubMedGoogle Scholar